Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 939-606-3
CAS number: 96690-74-3
Absorption: 100% via oral route, 1% via dermal routeDistribution: Unquantified amounts of three different alkyl sulfates were found only in the kidney and the liver.Metabolism: Alkylsulfates have a common metabolic fate that involves hydrolysis of the ether bond between the fatty alcohol and the sulfate chain followed by degradation of the alkylchain via beta- and omega-oxidation to the respective C2 and C4 (even numbered AS) and the C3 and C5 (odd numbered AS). These products are mainly sulfated and excreted. C2- fragments may enter the C2 pool of the body and are either oxidized to CO2 or found in the body. About 10 to 20% of the dose usually is eliminated as inorganic sulfate. Excretion: The majority was excreted via urine. Only smaller amounts are excreted via the faeces. Elimination is fastest for C12 (complete within approx. 6 h) but decreases for other chain length.
To draw a coherent picture of the toxicokinetic, metabolism and
distribution of the various members of the alkyl sulfates this endpoint
is covered by read across to structurally related alkyl sulfates (AS).
The possibility of a read-across to other alkyl sulfates in accordance
with Regulation (EC) No 1907/2006 Annex XI 1.5. Grouping of substances
and read-across approach was assessed. In Annex XI 1.5 it is given that
a read-across approach is possible for substances, whose
physicochemical, toxicological and ecotoxicological properties are
likely to be similar or follow a regular pattern as a result of
structural similarity. The AS reported within the AS category show
structural similarity. The alkyl chain length in the alkyl sulfate
category varies from C8 to C18. In addition most chemicals of this
category are not defined substances, but mixtures of homologues with
different alkyl chain lengths (UVCBs). The most important common
structural feature of the category members is the presence of a
predominantly linear aliphatic hydrocarbon chain with a polar sulfate
group, neutralized with a counter ion. This structural feature confers
the surfactant properties of the alkyl sulfates. The surfactant property
of the members of the AS category in turn represent the predominant
attribute in mediating effects on mammalian health. Due to the
structural similarities also the disposition within the body is
comparable throughout the category. The AS of the AS category also have
similar physico-chemical, environmental and toxicological properties,
validating the read across approach within the category. The approach of
grouping different AS for the evaluation of their toxicokinetics,
metabolism and distribution as well as their effects on human health and
the environment was also made by the OECD in the SIDS initial assessment
profile  and by a voluntary industry programme carrying out Human and
Environmental Risk Assessments (HERA [2). Data reported within the
discussion below summarize the information of the SIDS and HERA reports.
After oral administration, alkyl sulfates are well absorbed in
rats, dogs and humans (SIDS, 2007). This was indicated by excretion of
up to 98% of the dose administered (maximum for C12AS Na) in the urine
and by comparison of excretion after oral and i.v. or i.p. application
for several alkyl sulfates. Hence, oral absorption is assumed to be 100%.
Absorption by the percutaneous route is limited, since anionic
surfactants tend to bind to the skin surface (SIDS, 2007). Early studies
with isolated human skin were unable to detect penetration of a
homologous series of AS, ranging from C8 to C18 carbon chain lengths.
Animal studies confirmed a low level of percutaneous absorption of AS.
Less than 0.4% of a 3 μmol dose of 35S-labeled C12
ASO4Na was percutaneously absorbed in guinea pigs, based on recovery of
the radiolabel in urine, faeces and expired air. Studies with rats
indicated that pre-washing of the skin with surfactant enhanced AS skin
penetration. Early studies with isolated human skin (not specified
further) were unable to detect dermal penetration of C12AS Na.
Based on experimental data on animals and humans, a default
assumption of 1% dermal absorption was taken for deriving the DNEL.
Since dermal absorption decreases with increasing concentration of a
solution, this percentage can be used for workers as a worst case
After oral administration of 14.4 mg/kg bw of the erythromycin
salt of C16AS to dogs or 250 mg/person to humans, radioactivity in
plasma was maximal within 30 minutes to 2 hours of exposure in both
species indicating rapid absorption (SIDS, 2007). The plasma
concentration declined rapidly afterwards and reached 10 % of the
maximum concentration after 6 hours, indicating rapid elimination.
Whole body autoradiography has been performed to follow the
distribution of 35S-C10AS K, C12AS K and C18AS K or their metabolites
within the body with time in experiments with rats after i.p. injection.
For all compounds the only organs, where radioactivity was detected were
liver and kidney. The levels (not quantified) were highest 1 h after
application. C10AS K was cleared from tissues more rapidly than C18AS K.
After 6 hours, only traces of the C10AS K salt remained in the kidney,
whereas it took 12 hours for the C18AS K salt to be cleared from the
Alkyl sulfates are extensively metabolized in rats, dogs and
humans. This was tested with radiolabelled C10, C11, C12, C16 and C18
alkyl sulfates, potassium salts (SIDS, 2007).
The postulated mechanism is degradation involving omega-oxidation,
followed by beta-oxidation, to yield metabolites with chain lengths of
C2 and C4 for even-chain carbon alkyl sulfates. The major metabolite for
even-chained alkyl sulfates was identified as the 4-carbon compound,
butyric acid 4-sulfate. The 4-butyrolactone has been found as a minor
metabolite which is also formed after application of butyric acid
4-sulfate. Dog and human urine also contained one other minor
metabolite, glycolic acid sulfate.
Metabolism of odd numbered chains (specifically, C11) in rats was
postulated to follow a similar omega-, beta-degradation pathway:
propionic acid-3-sulfate was the major urinary metabolite and pentanoic
acid-5-sulfate and inorganic sulfate were minor metabolites.
The C2 fragments enter the C2 pool of the body and are either
oxidized to CO2 or found in the body. About 10 to 20% of the dose
usually is eliminated as inorganic sulfate.
The major path of excretion of the alkyl sulfates is the urine.
The data show, that there are only minor differences for the alkyl
sulfates of different chain lengths in the overall excretion after i.p.
application. There are also no major differences in overall excretion
between male and female rats or after oral, intraperitoneal or
intravenous application. The rate of excretion in the urine, however, is
somewhat different. After oral as well as i.p. application, excretion of
the C12 compound is complete within 6 hours. In contrast the excretion
amounts only to about 60% (C10), 40% (C11), 15% (C18) after i.p.
application, and to 25% for C11 or C18 6 hours after oral application.
This indicates faster metabolism of the C12 compound than for the other
Lower amounts of the alkyl sulfates are excreted via the faeces
within 48 hours after oral application for the C12, C16 and C18
compounds. The lowest value was obtained for the C12, while the highest
values with considerable variation of 2.5 - 19.9% (2 m, 2f) were found
for C11. In the bile from <1 to 7.7% (highest amount with C11) of the
dose applied was found up to 6 hours after i.v. application, indicating,
that the amounts in faeces are mainly due to metabolism and not to
unabsorbed compound. In addition the distribution of label in urine and
faeces from orally administered potassium dodecyl-35S-sulfate (C12A35S
K) was similar in both antibiotic-treated and untreated rats, indicating
that the intestinal flora does not play a significant role in the
metabolism of this compound.
Based on the above mentioned data, tissue accumulation can be
Influence of counter ions on ADME
Due to dissociation, there is no effect of the counter ion on
absorption, distribution, metabolism and excretion of the alkyl sulfate
moiety expected (Hera, 2002). This is supported by comparable results
achieved with alkyl sulfates having different counter ions reported
within this section.
Discussion on absorption rate:
Absorption by the percutaneous route is limited, since anionic
surfactants tend to bind to the skin surface (SIDS, 2007). Both, studies
with isolated human skin and animal tests confirmed a low level of
percutaneous absorption. Based on experimental data on animals and
humans, a default assumption of 1% dermal absorption was taken for
deriving the DNEL. Since the dermal absorption decreases with increasing
concentration of a solution this percentage can be used for workers as a
worst case approach.
 SIDS initial assessment profile,
 (HERA Draft report, 2002);
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again